Chemo Regimen for Ovarian Cancer Raleigh NC

Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say. Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients in Raleigh, according to the new study findings.

Robert Dean Matthews, MD
(919) 350-8712
2609 Lochmore Dr
Raleigh, NC
Specialties
Urology
Gender
Male
Education
Medical School: Vanderbilt Univ Sch Of Med, Nashville Tn 37232
Graduation Year: 1986

Data Provided by:
Mark W Jalkut
(919) 782-1255
4301 Lake Boone Trl
Raleigh, NC
Specialty
Urology

Data Provided by:
Brian Charles Bennett, MD
(919) 881-0287
4505 Fair Meadows Ln Ste 101
Raleigh, NC
Specialties
Urology
Gender
Male
Education
Medical School: Vanderbilt Univ Sch Of Med, Nashville Tn 37232
Graduation Year: 1989

Data Provided by:
Stephen J Stafford
(919) 790-5500
3320 Wake Forest Rd
Raleigh, NC
Specialty
Urology

Data Provided by:
Joseph M Khoury, MD
(919) 571-6460
4201 Lake Boone Trl Ste 205
Raleigh, NC
Specialties
Urology
Gender
Male
Education
Medical School: Georgetown Univ Sch Of Med, Washington Dc 20007
Graduation Year: 1981

Data Provided by:
Philip Mayes Newhall, MD
(919) 782-1255
4301 Lake Boone Trl Ste 300
Raleigh, NC
Specialties
Urology
Gender
Male
Education
Medical School: Boston Univ Sch Of Med, Boston Ma 02118
Graduation Year: 1994

Data Provided by:
Timothy Bukowski, MD
(919) 785-1888
2406 Blue Ridge Rd Ste 190
Raleigh, NC
Specialties
Urology
Gender
Male
Education
Medical School: Suny At Buffalo Sch Of Med & Biomedical Sci, Buffalo Ny 14214
Graduation Year: 1987

Data Provided by:
Dr.Scott Baker
(919) 782-1255
4301 Lake Boone Trl # 300
Raleigh, NC
Gender
M
Speciality
Urologist
General Information
Hospital: Rex
Accepting New Patients: Yes
RateMD Rating
1.5, out of 5 based on 1, reviews.

Data Provided by:
Richard D Kane
(919) 782-1255
4301 Lake Boone Trl
Raleigh, NC
Specialty
Urology

Data Provided by:
Douglas Charles Leet, MD
(919) 790-5500
3320 Wake Forest Rd Ste 320
Raleigh, NC
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Chicago, Pritzker Sch Of Med, Chicago Il 60637
Graduation Year: 1975

Data Provided by:
Data Provided by:

Chemo Regimen for Ovarian Cancer

Provided By:

SUNDAY, Sept. 20 (HealthDay News) -- Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say.

Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients, according to the new study findings.

This phase 3 study of 637 women compared the two approaches. The participants had advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

The 320 patients in the conventional regimen group received six cycles of paclitaxel (180 milligrams per meter squared; three-hour intravenous infusion). The 317 patients in the dose-dense group received paclitaxel (80 milligrams per meter squared; one-hour intravenous infusion) on days one, eight and 15. Both groups received carboplatin on day one of a 21-day cycle.

The patients in the dose-dense group had longer median progression-free survival than those in the standard treatment group (28 months versus 17 months), and longer overall survival at three years (72 percent versus 65 percent). This means that women in the dose-dense group had a 29 percent lower risk of cancer progression and a 25 percent lower risk of death, the authors explained.

Toxicity forced 113 patients in the dose-dense group and 69 patients in the conventional therapy group to stop treatment, the researchers noted. Severe anemia occurred in 214 patients (69 percent) in the dose-dense group and in 137 (44 percent) of the standard therapy group.

The survival benefits seen in the dose-dense group are rare in patients with advanced ovarian cancer, and this regimen offers a new treatment option for women with advanced epithelial ovarian cancer, concluded Dr. Noriyuki Katsumata, of the National Cancer Center Hospital in Tokyo, and colleagues.

The study, published in an upcoming print issue of The Lancet, was released online Sunday to coincide with the European Cancer Organization meeting held Sept. 20 to 24 in Berlin.

"The use of such dose-dense therapy should be decided on an individual basis together with other options for women with advanced-stage ovarian cancer," Dr. Michael A. Bookman, of the Arizona Cancer Center in Tucson, wrote in an accompanying commentary in The Lancet.

More information

The U.S. National Cancer Institute has more about ovarian cancer.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com